As noted by ECDC as well as the technical working group on COVID-19 diagnostic tests, the predictive value of rapid antigen test is highest in settings where SARS-CoV-2 prevalence, that is, the number of cases at a certain point of time, is high, and false positives may occur when the prevalence is low. While, as a result of the emergence of Omicron, the virus is currently circulating at very high levels, circulation may decrease over the coming months. It is thus necessary for the Commission, supported by ECDC, the Health Security Committee and its technical working group on COVID-19 diagnostic tests, to monitor these developments closely.
Recital 16, Regulation (EU) 2022/256
In forcesince 22 Feb 2022